A U.S. Food and Drug Administration decision to grant broader emergency use authorization to Qorvo Biotechnologies’ COVID diagnostic test is significantly expanding the product’s reach.
Read More
In the category of COVID innovation, Greensboro-based Qorvo Biotechnologies has received a $4.1 million follow-on contact from the National Institutes of Health to support its COVID-related diagnostic test platform. The agreement is through the NIH’s Rapid Acceleration of Diagnostics initiative.
Read More
Qorvo Biotechnologies has landed another contract – this one worth more than $4 million – from the National Institutes of Health to continue development of its diagnostic test platform which could be used for COVID-related testing.
Read More
A new rapid antigen test that can identify whether a patient is COVID-19 positive in 20 minutes developed by Qorvo Biotechnologies has received emergency use authorization from the FDA, and the NIH awarded a $24.4 million contract to the company for its production.
Read More
